Dr Grivas on Sacituzumab Govitecan Plus Pembrolizumab in Metastatic Urothelial Cancer

Petros Grivas, MD, PhD, discusses findings from the primary analysis of cohort 3 of the phase 2 TROPHY U-01 trial in patients with metastatic urothelial cancer.

Related Keywords

Petros Grivas ,Genitourinary Cancers Program ,Division Of Oncology ,Department Of Medicine ,University Of Washington School Medicine ,Clinical Research Division ,Fred Hutch Cancer Center ,University Of Washington Medicine ,Washington Medicine ,Washington School ,D ,Phd ,Trophyu 01 Trial ,Nct03547973 ,Patients With Metastatic Urothelial Cancer ,Sacituzumab Govitecan Plus Pembrolizumab ,